Yuchun Lee - 08 Apr 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
08 Apr 2022
Net transactions value
-$791,580
Form type
4
Filing time
12 Apr 2022, 16:07:18 UTC
Previous filing
08 Apr 2022
Next filing
14 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $163,080 +2,000 +107% $81.54 3,875 08 Apr 2022 Direct
transaction VRTX Common Stock Sale $115,627 -418 -11% $276.62 3,457 08 Apr 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $119,235 -430 -12% $277.29 3,027 08 Apr 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale $195,552 -700 -23% $279.36 2,327 08 Apr 2022 Direct F1, F2, F5
transaction VRTX Common Stock Sale $126,727 -452 -19% $280.37 1,875 08 Apr 2022 Direct F1, F2, F6
transaction VRTX Common Stock Options Exercise $163,080 +2,000 +107% $81.54 3,875 11 Apr 2022 Direct
transaction VRTX Common Stock Sale $257,985 -922 -24% $279.81 2,953 11 Apr 2022 Direct F1, F2, F7
transaction VRTX Common Stock Sale $271,640 -968 -33% $280.62 1,985 11 Apr 2022 Direct F1, F2, F8
transaction VRTX Common Stock Sale $30,974 -110 -5.5% $281.58 1,875 11 Apr 2022 Direct F1, F2, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -2,000 -17% $0.000000 10,000 08 Apr 2022 Common Stock 2,000 $81.54 Direct F10
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -2,000 -20% $0.000000 8,000 11 Apr 2022 Common Stock 2,000 $81.54 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
F2 Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $276.62 (range $276.08 to $276.81).
F4 Open market sales reported on this line occurred at a weighted average price of $277.29 (range $277.16 to $277.46).
F5 Open market sales reported on this line occurred at a weighted average price of $279.36 (range $278.86 to $279.74).
F6 Open market sales reported on this line occurred at a weighted average price of $280.37 (range $280.06 to $281.02).
F7 Open market sales reported on this line occurred at a weighted average price of $279.81 (range $279.29 to $280.18).
F8 Open market sales reported on this line occurred at a weighted average price of $280.62 (range $280.31 to $281.28).
F9 Open market sales reported on this line occurred at a weighted average price of $281.58 (range $281.55 to $281.58).
F10 Fully vested.